Pharmacokinetics (PK), safety and overall response rate (ORR) achieved with subcutaneous (SC) administration of rituximab in combination with chemotherapy were comparable to those achieved with intravenous (IV) administration in patients (pts) with follicular lymphoma (FL) in the first-line setting: Stage 1 results of the phase III SABRINA study

被引：0

作者：

Davies, A. J. ^{[1
]}

Merli, F. ^{[2
]}

Mihaljevic, B. ^{[3
]}

Siritanaratkul, N. ^{[4
]}

Solal-Celigny, P. ^{[5
]}

Boehnke, A. ^{[6
]}

Berge, C. ^{[6
]}

McIntyre, C. ^{[7
]}

Barrett, M. ^{[7
]}

MacDonald, D. ^{[8
]}

机构：

[1] Univ Southampton, Canc Res UK Ctr, Fac Med, Southampton SO9 5NH, Hants, England

[2] Azienda Osped Santa Maria Nuova, Hematol Unit, Reggio Emilia, Italy

[3] Clin Ctr Serbia, Sch Med, Clin Hematol, Belgrade, Serbia

[4] Siriraj Hosp, Div Hematol, Dept Med, Bangkok, Thailand

[5] Ctr J Bernard, Le Mans, France

[6] F Hoffmann La Roche & Co Ltd, Clin Dev, CH-4002 Basel, Switzerland

[7] Roche Prod Ltd, Clin Pharmacol, Welwyn Garden City AL7 3AY, Herts, England

[8] QEII Hlth Sci Ctr, Halifax, NS, Canada

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2013年 / 161卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：7 / 8

页数：2

共 6 条

[1] Pharmacokinetics (PK), Safety and Overall Response Rate (ORR) Achieved with Subcutaneous (SC) Administration of Rituximab in Combination with Chemotherapy Were Comparable to Those Achieved with Intravenous (IV) Administration in Patients (pts) with Follicular Lymphoma (FL) in the First-Line Setting: Stage 1 Results of the Phase III SABRINA Study (BO22334)
Davies, Andrew
Merli, Francesco
Mihaljevik, Biljana
Siritanaratkul, Noppadol
Solal-Celigny, Philippe
Boehnke, Axel
Berge, Claude
McIntyre, Christine
Barrett, Martin
Macdonald, David
BLOOD, 2012, 120 (21)
[2] SUBCUTANEOUS RITUXIMAB AND CHEMOTHERAPY ACHIEVES SIMILAR OVERALL RESPONSE RATES TO INTRAVENOUS RITUXIMAB IN FIRST-LINE FOLLICULAR LYMPHOMA: EFFICACY AND SAFETY RESULTS OF THE PHASE III SABRINA STUDY
Davies, A.
Merli, F.
Mihaljevic, B.
Mercadal, S.
Solal-Celigny, P.
Boehnke, A.
Berge, C.
Cambon, N.
Macgregor, L.
Brewster, M.
Barrett, M.
MacDonald, D.
HAEMATOLOGICA, 2014, 99 : 225 - 225
[3] Subcutaneous Rituximab and Chemotherapy Achieves Similar Overall Response Rates to Intravenous Rituximab in First-Line Follicular Lymphoma: Efficacy and Safety Results of the Phase III SABRINA Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (08) : 6 - 7
[4] SUBCUTANEOUS RITUXIMAB AND CHEMOTHERAPY ACHIEVES SIMILAR TROUGH LEVELS, SAFETY, AND RESPONSE AS INTRAVENOUS RITUXIMAB IN FIRST-LINE FOLLICULAR LYMPHOMA: STAGE 1 RESULTS OF THE PHASE 3 SABRINA STUDY
Davies, A.
Merli, F.
Mihaljevic, B.
Siritanaratkul, N.
Solal-Celigny, P.
Boehnke, A.
Berge, C.
McIntyre, C.
Barrett, M.
MacDonald, D.
HAEMATOLOGICA, 2013, 98 : 131 - 132
[5] Final Results of the BP22333 Study Demonstrate Non-Inferior Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Administration of Rituximab Compared with Intravenous (IV) Administration As Maintenance Therapy in Patients with Follicular Lymphoma (FL)
Salar, Antonio
Avivi, Irit
Larouche, Jean-Francois
Janikova, Andrea
Pereira, Juliana
Brewster, Mike
Catalani, Olivier
McIntyre, Christine
Sayyed, Pakeeza
Haynes, Andrew
BLOOD, 2012, 120 (21)
[6] Non-Inferior Pharmacokinetics with Comparable Safety and Response Rates for Subcutaneous (SC), Compared with Intravenous (IV), Rituximab in Combination with Fludarabine and Cyclophosphamide (FC) in Patients (Pts) with Untreated Chronic Lymphocytic Leukemia (CLL): Part 2 of the Phase Ib SAWYER Study (BO25341)
Assouline, Sarit
Buccheri, Valeria
Delmer, Alain
Gaidano, Gianluca
Brewster, Michael
Catalani, Olivier
Li, Sai
McIntyre, Christine
Sayyed, Pakeeza
Badoux, Xavier C.
BLOOD, 2014, 124 (21)

← 1 →